54930022EOITNKSIGH562025-07-012026-06-30iso4217:GBP54930022EOITNKSIGH562024-07-012025-06-30iso4217:GBPxbrli:shares54930022EOITNKSIGH562024-06-30ifrs-full:IssuedCapitalMember54930022EOITNKSIGH562024-06-30ifrs-full:SharePremiumMember54930022EOITNKSIGH562024-06-30ifrs-full:TreasurySharesMember54930022EOITNKSIGH562024-06-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember54930022EOITNKSIGH562024-06-30ifrs-full:ReserveOfCashFlowHedgesMember54930022EOITNKSIGH562024-06-30ifrs-full:RetainedEarningsMember54930022EOITNKSIGH562024-06-30ifrs-full:EquityAttributableToOwnersOfParentMember54930022EOITNKSIGH562024-06-30ifrs-full:NoncontrollingInterestsMember54930022EOITNKSIGH562024-06-3054930022EOITNKSIGH562024-07-012025-06-30ifrs-full:IssuedCapitalMember54930022EOITNKSIGH562024-07-012025-06-30ifrs-full:SharePremiumMember54930022EOITNKSIGH562024-07-012025-06-30ifrs-full:TreasurySharesMember54930022EOITNKSIGH562024-07-012025-06-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember54930022EOITNKSIGH562024-07-012025-06-30ifrs-full:ReserveOfCashFlowHedgesMember54930022EOITNKSIGH562024-07-012025-06-30ifrs-full:RetainedEarningsMember54930022EOITNKSIGH562024-07-012025-06-30ifrs-full:EquityAttributableToOwnersOfParentMember54930022EOITNKSIGH562024-07-012025-06-30ifrs-full:NoncontrollingInterestsMember54930022EOITNKSIGH562025-06-30ifrs-full:IssuedCapitalMember54930022EOITNKSIGH562025-06-30ifrs-full:SharePremiumMember54930022EOITNKSIGH562025-06-30ifrs-full:TreasurySharesMember54930022EOITNKSIGH562025-06-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember54930022EOITNKSIGH562025-06-30ifrs-full:ReserveOfCashFlowHedgesMember54930022EOITNKSIGH562025-06-30ifrs-full:RetainedEarningsMember54930022EOITNKSIGH562025-06-30ifrs-full:EquityAttributableToOwnersOfParentMember54930022EOITNKSIGH562025-06-30ifrs-full:NoncontrollingInterestsMember54930022EOITNKSIGH562025-06-3054930022EOITNKSIGH562025-07-012026-06-30ifrs-full:IssuedCapitalMember54930022EOITNKSIGH562025-07-012026-06-30ifrs-full:SharePremiumMember54930022EOITNKSIGH562025-07-012026-06-30ifrs-full:TreasurySharesMember54930022EOITNKSIGH562025-07-012026-06-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember54930022EOITNKSIGH562025-07-012026-06-30ifrs-full:ReserveOfCashFlowHedgesMember54930022EOITNKSIGH562025-07-012026-06-30ifrs-full:RetainedEarningsMember54930022EOITNKSIGH562025-07-012026-06-30ifrs-full:EquityAttributableToOwnersOfParentMember54930022EOITNKSIGH562025-07-012026-06-30ifrs-full:NoncontrollingInterestsMember54930022EOITNKSIGH562026-06-30ifrs-full:IssuedCapitalMember54930022EOITNKSIGH562026-06-30ifrs-full:SharePremiumMember54930022EOITNKSIGH562026-06-30ifrs-full:TreasurySharesMember54930022EOITNKSIGH562026-06-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember54930022EOITNKSIGH562026-06-30ifrs-full:ReserveOfCashFlowHedgesMember54930022EOITNKSIGH562026-06-30ifrs-full:RetainedEarningsMember54930022EOITNKSIGH562026-06-30ifrs-full:EquityAttributableToOwnersOfParentMember54930022EOITNKSIGH562026-06-30ifrs-full:NoncontrollingInterestsMember54930022EOITNKSIGH562026-06-30
Genus plc / Annual Report 2026
Sustainably
nourishing
the world
Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
STRATEGIC REPORT
2026 Highlights
Genus at a Glance
Our Markets and Business Model
Chairman’s Statement
Chief Executive’s Review 
Strategic Framework 
Key Performance Indicators 
Operating Reviews 
Chief Financial Officer’s Review 
People and Culture 
Sustainability Report 
TCFD Report 
Stakeholder Engagement 
Non-Financial and Sustainability
Information Statement

Section 172 Statement 
Principal Risks and Uncertainties 
Going Concern and
Viability Statement

CORPORATE GOVERNANCE
Chairman’s Letter 
Board of Directors and
Company Secretary

Genus Executive Leadership Team 
The Board at a Glance 
Nomination Committee Report 
Audit & Risk Committee Report 
Remuneration Committee Report 
Directors’ Report 
Directors’ Responsibilities 
FINANCIAL STATEMENTS
See pages 101 to 182
ADDITIONAL INFORMATION
See pages 183 to 192
We pioneer advances
in animal genetics to
help build a more
sustainable global
food system.
By applying cutting-edge science and innovation,
we enable farmers to produce high-quality meat and
milk more efficiently, using fewer natural resources
and reducing their environmental impact. Our work
supports a future where growing populations can be
nourished responsibly, balancing productivity with
long-term sustainability.
Links to a page in this report
Links to online content
Quick reads
NAVIGATING THIS REPORT
1Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Group revenue
£658.1m
2025: £672.8m Change: -2%
Adjusted profit before tax
£100.2m
2025: £74.3m Change: 35%
Dividend per share
35.2p
2025: 32.0p Change: 10%
Statutory profit before tax
£310.5m
2025: £28.5m Change: 989%
Free cash flow
£62.0m
2025: £40.9m Change: 52%
Adjusted basic earnings per share
110.3p
2025: 81.8p Change: 35%
1 Adjusted results are the Alternative Performance Measures (‘APMs’) used by the Board
to monitor underlying performance at a Group and operating segment level, which
are applied consistently throughout. These APMs should be considered in addition to,
and not as a substitute for or as superior to statutory measures. For more information
on APMs, see APM Glossary.
For more information, visit our website
genusplc.com
2026
highlights
2Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Pioneering
animal genetic
improvement
WHAT WE DO
We produce elite animal
genetics and sell them to
farmers, along with services
that help them to maximise
the value of those genetics.
Our customers access our
genetics by buying live
animals, semen or embryos,
to use in their own breeding
programmes.
HOW WE DO IT
We own elite animal herds that contain our
proprietary genetics. Our goal is to drive continuous
genetic improvement in these herds, by breeding
together the individuals with the highest genetic
potential to produce the next generation.
To identify the highest-potential animals, we score
each one on its observable (or phenotypic) traits
and its genetic (or genomic) traits. This includes
analysing its DNA to identify the presence or
absence of genetic markers linked to specific
characteristics. We then calculate the individual’s
Estimated Breeding Value (‘EBV’) based on these
scores and select the individuals with the highest
EBVs for breeding.
We also develop proprietary technologies
that accelerate genetic gain or deliver other
value-added services or products to farmers.
Our sexing technology is a good example,
enabling bull semen to be sorted into female
sex (valued by the dairy industry) and male sex
(valued by the beef industry). We can either
apply our technological solutions to our genetics
before selling them to customers or license
the solutions to customers for their own use.
OUR COMPETITIVE
ADVANTAGES
We have significant strengths, which differentiate
us in our markets and create a substantial
barrier for new entrants. These include our:
• world-class proprietary genetics, intellectual
property and technical know-how;
• well-invested global supply chain, enabling
customers to trust us to supply large volumes
of elite genetics with high health status;
• scale, which means we can accelerate genetic
gain by leveraging our phenotypic and genotypic
data collection to improve the precision of our
genomic selection; and
• our customer and research partner relationships,
many of which we have nurtured over decades
of mutual collaboration.
Genus at a Glance
Our animals exhibit valuable traits, such as
increased feed conversion, growth rates and
resistance to disease. This helps our customers
to raise healthier animals and produce more
high-quality protein for the same volume of
resources, such as feed, water and land.
Our genetics make up a small proportion of a
farmer’s cost base. We therefore improve farmers’
profitability, while reducing the environmental
impact of animal protein production and
making the food supply more resilient.
See pages 5 to 7
3Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Genus at a Glance continued
OUR COMMERCIAL DIVISIONS
Our Porcine and Bovine divisions operate
under the brand names PIC and ABS,
respectively. As their market structures
are different, PIC and ABS employ
different business models and have
different financial profiles.
1 Average number of employees (excluding agency staff and contractors).
2 Revenue Includes Joint Ventures.
3 Adjusted operating profit includes product development.
4 Excluding Joint Ventures.
PIC ABS
Number of employees
800+ 2,000+
Adjusted revenue
£355.8m £299.8m
Adjusted operating profit
£130.8m £22.9m
Adjusted operating margin
30.9% 7.5%
See pages 16 to 17 for
our PIC divisional review
See pages 18 to 19 for
our ABS divisional review
4Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Global footprint
Genus at a Glance continued
Our business is global
and we have a supply
chain and commercial
operations to match.
Key to regions
EMEA
North America
Asia
Latin America
Key to operations
PIC
PIC Joint ventures
ABS
R&D
5Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Long-term
growth drivers
in our markets
Our Markets and Business Model
02
Increasing demand
for healthier and
higher-welfare foods
Consumers increasingly want healthier and more
sustainable products that are produced with a
focus on animal welfare, provenance and reduced
drug usage. This increases farmers’ demand for
genetically superior animals that are naturally
more disease resistant and productive.
See pages 6 to 7
CONSUMERS
01
Increasing demand for
animal protein
The Food and Agriculture Organization of the
United Nations estimates that total global
consumption of pork, milk and beef will increase
by approximately 1-2% per annum over the next
decade. This is being driven by continued global
population growth and urbanisation, creating
increased demand for third-party produced food,
and consumers seeking a more varied and
nutritious diet.
See pages 6 to 7
PRODUCERS
03
Increasing consolidation
and technification
Animal protein production tends to consolidate
over time to a smaller number of larger farmers.
These larger farmers, or farming groups, are
typically more data-driven and progressive in
their use of elite genetics and other technologies
to drive operational efficiency. Our addressable
market therefore tends to grow as market
consolidation occurs.
See pages 6 to 7
SUSTAINABILITY
05
Animal protein production
needs to be more efficient
Animal protein production is increasingly subject
to sustainability demands from regulators and
consumers. Increased use of elite genetics is a key
component of increasing productivity and animal
welfare within the industry.
See pages 28 to 40
1 Achieving SDG2 without breaching the 1.5˚C threshold:
A Global Roadmap (10 December 2023).
The livestock sector
requires intensified
productivity via
improved genetics and
feeding practices, to
reduce resource usage.
UN Food and Agriculture Organization
04
Increasing vertical
integration
The animal protein supply chain tends to
vertically integrate over time with increasingly
deep relationships between farmers, processors
and retailers. This makes farmers more likely to
value elite genetics, as vertical integration means
they can share in the benefit of traits such as
carcass quality that accrue downstream in the
supply chain.
See pages 6 to 7
6Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Multiplication
Objectives vary at each
level of the pyramid
Genetic improvement
Pure line expansion
Cross breeding for
parent (F1) production
F1 hybrid females
to terminal sires
Slaughter pigs
Boars
Boar
1yr
4yrs
studs
Grandparent
(GP)
Great
Grandparent
(GGP)
Sows in inventory
1
10
Parent (P) 100
2,500
produced
Semen
Commercial production
Nucleus
Figure 1 - PIC presence in the pig breeding pyramid
PIC owned/leased
Contracted
Customer owned
Porcine
What we sell
We sell male and female pigs,
as well as semen. We also have
teams of technical specialists,
such as veterinarians and
nutritionists, who advise our
customers on how to improve
the efficiency and robustness
of their farming systems.
Route to market
We distribute directly to customers
as well as through distributors
and franchisees in some markets.
Our franchise partners pay us
a variable fee for the use of
PIC’s brand and genetics.
How we sell
We sell under two models:
• The upfront model, through
which PIC receives the full
fair value of the animal or
product immediately.
• The royalty model, through
which PIC sells the animal or
product at cost and then
receives royalties based on
future events, typically a
piglet being weaned from
the original genetics.
The royalty model decreases
our exposure to cyclical
producer profitability and
increases our revenue visibility
and customer retention.
Our opportunity
• Expand our genetic lead by
driving genetic improvement
faster than competitors.
• Grow market share by (1)
partnering with progressive
customers who are winning
production share, (2) increasing
our wallet share with these
customers, (3) winning new
customers and (4) expanding
into new markets.
• Continue to grow our Joint
Venture in China with a local
supply chain and royalty
focused sales team.
• Launch PRP, once we
have built the necessary
regulatory portfolio.
• Explore technology-led
solutions to other diseases
and challenges facing
pork producers.
Top 10 pork production markets
1.
5.
9.
2.
6.
10.
3.
7.
4.
8.
Our Markets and Business Model continued
Porcine production is relatively
consolidated and vertically
integrated, which means greater
demand for elite genetics.
Production system
Pork tends to be produced
in pyramids, as shown in
the diagram (Figure 1).
Genetic improvement is driven
at the top of the pyramid. PIC
has three highly bio-secure elite
farms in North America where we
conduct genomic selection on our
proprietary herds of pure line pigs.
The best animals are retained
in our elite farms whilst other
top-performers are cascaded
down the pyramid, as follows.
High-performing males are
sent from the elite farms to
boar studs. Here, semen is
collected and used throughout
the rest of the pyramid to
artificially inseminate females.
High-performing females
are sent from our elite farms
to nucleus farms. Here, their
numbers are expanded
so we have sufficient pure
line animals to supply our
multiplication partners.
Pure line females from
nucleus farms are sent to
multiplication farms where
they are cross-bred with semen
from males of a different line.
Cross-bred female offspring
from the multiplication farms are
then sent to commercial farms
where they are inseminated
with terminal boar semen
to produce offspring that
are sent to slaughter.
PIC only owns proprietary assets
at the top of the pyramid. This
delivers high return on invested
capital (‘ROIC’) and reduces
our exposure to the financial
risks of pork production,
such as feed costs, disease
and pork price volatility.
Our proprietary footprint,
coupled with long-standing
nucleus and multiplication
relationships, means we have
a highly responsive global
supply chain that can supply
high-volume elite genetics
with high health status.
We estimate that PIC has
~16% share of the global
porcine genetics market.
7Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Our Markets and Business Model continued
Bovine
Our dairy opportunity
• Drive genetic improvement
faster than competitors.
• Continue executing actions to
structurally improve margins,
ROIC and cash generation.
• Drive increased adoption of
sexed, beef-on-dairy and
Y-skew by dairy farmers.
• Grow the market share of
our IntelliGen third-party
sexing solutions.
Top 10 dairy production markets
1.
5.
9.
2.
6.
10.
3.
7.
4.
8.
Beef production system
Beef production is less
homogeneous than dairy
systems and utilises many
breeds. The supply chain is
also less vertically integrated
than either dairy or pork. Use of
advanced genetics and artificial
insemination in the beef industry
is lower because producers are
in aggregate less consolidated
and technified than dairy.
Beef production is mainly from
pure-bred beef animals, although
an increasing portion is coming
from beef-on-dairy usage.
Our beef opportunity
• Drive genetic improvement
faster than competitors.
• Drive increased adoption of
sexed, beef-on-dairy and
Y-skew by dairy farmers by
demonstrating the superiority
of our proprietary beef genetics
across the value chain, through
trials and partnerships.
• Develop more ‘pull-through’
partnerships with downstream
partners in the value chain (see
How we sell below).
Top 10 beef production markets
1.
5.
9.
2.
6.
10.
3.
7.
4.
8.
What we sell
We predominantly sell straws of
semen (conventional and sexed)
for artificial insemination use in
the dairy and beef industries.
We also sell embryos, which
contain elite male and female
genetics, to highly progressive
farmers who are focused on
maximising the rate of genetic
improvement in their herds. We
monetise our proprietary sexing
technology in three ways:
1 sexing semen from our
own bulls;
2 sexing semen for third-party
bulls; and
3 licensing our technology to
third parties.
We also offer adjacent
services and products to
farmers through our artificial
insemination technicians,
who visit customer farms.
Route to market
We distribute directly to customers
and through distributors.
How we sell
The majority of our bovine sales
are transactional, although
there is a growing share under
multi-year contracts. In beef
we also employ ‘pull-through’
contracts. The beef industry is
less vertically integrated and the
value of beef genetics (e.g. a
premium for marbling) tends to
accrue to downstream entities
such as processors, packers and
retailers. If we can demonstrate
this increased economic
value, as well as sustainability
benefits, to these downstream
entities, they can incentivise
their upstream suppliers to
use ABS genetics. By winning
downstream we can therefore
‘pull-through’ our genetics.
We estimate that ABS has
~8% share of the global
bovine genetics market.
Dairy production is typically
more consolidated than beef
production but both are
significantly more fragmented
than pork production. The
bovine genetics landscape is
also different to porcine, with
many more breeds in regular
use and large genetic co-ops
having significant market share.
Dairy production system
Dairy farmers typically use
artificial insemination to create
pregnancies in their cows. Cows
then produce milk for about
ten months after giving birth.
This milk is generally marketed
to a third-party processor,
who collects, processes,
stores and sells the milk or
milk products (such as cheese
and butter) to subsequent
parts of the value chain.
Farmers either retain the female
calves from dairy cows, to grow
or maintain their dairy herd, or
sell them to the beef industry
alongside the male calves.
Over the last decade, progressive
dairy farmers have increasingly
utilised sexed semen to actively
manage the sex of their dairy
cow offspring. They inseminate
their high-performing cows with
X-skew sexed semen, which has
a significantly greater proportion
of sperm carrying a female
chromosome, to increase the
probability that the resultant
offspring are females. These
female calves are likely to be
high performing and the farmers
retain them for their dairy herd.
Lower-performing cows, whose
offspring are less desirable
for the dairy herd, are instead
inseminated with conventional
semen or, increasingly, with
beef-on-dairy semen. Beef-
on-dairy semen contains
genetics with traits optimised
for the beef industry, such as
growth rate, feed efficiency and
carcass value. These calves are
therefore more valuable when
sold to the beef industry, which
creates more economic value
for the dairy farmer. A nascent
but exciting new market is sexed
beef-on-dairy genetics. Here,
Y-skew genetics are attractive
to the beef industry because
males tend to grow faster and
produce heavier carcasses.
How Fazenda
Petrópolis Is
Growing the
Future of Dairy
in Brazil
Discover how ABS customer
Fazenda Petrópolis is using
sexed genetics and data-
driven genetic selection to
support sustainable dairy
growth in Brazil.
Scan QR code
to read full
testimonial
8Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Chairman’s Statement
Performance and dividend
Both divisions delivered
operating profit growth.
PIC performed particularly
strongly, while ABS benefitted
from Phase 3 of the Value
Acceleration Programme (‘VAP’).
This contributed to adjusted
basic earnings per share (‘EPS’)
increasing by 34.8% in constant
currency to 110.3p (2025:
81.8p). This included £5.6m of
milestone payments received
from BCA in relation to the
formation of our Chinese joint
venture, without which adjusted
EPS increased by 24.5%.
Management’s focus on cash
generation and the receipt of
net cash proceeds of £98m
from BCA has further reduced
the Group’s debt, putting us in
a strong position to invest for
growth and to return surplus
funds to shareholders.
As part of our capital allocation
framework, we have reaffirmed
our commitment to a progressive
dividend policy funded by
organic free cash generation.
Our aim is to pay out 30-40%
of adjusted EPS, with an interim
dividend set at 35% of the full-
year dividend for the previous
year. In line with this policy,
the Board is recommending
a final dividend of 24.0p per
share (2025: 21.7p). Including
the interim dividend of 11.2p per
share, this gives a total for the
year of 35.2p per share (2025:
32.0p), up 10%. The total dividend
equates to 32% of adjusted EPS.
collaborating with a domestic
partner provides the best-
possible route to obtaining
the necessary approvals for
PRP in China. Genus has a
track record of successful joint
ventures, notably with Agroceres
in Brazil, so we understand
how to make them thrive.
These were significant advances
for PIC but it is also hugely
important that the business
has maintained its lead in
conventional genetics. Its
superior offer allows it to push
for market share across the
world, including laying the
foundations for expansion in
Southeast Asia. Increasing PIC’s
presence in that region is part
of our longer-term strategy
and the indications are good,
given PIC’s genetics perform
well in those countries. A
broader geographical presence
will also mean a greater
potential market for PRP.
Strategic priorities
As Jorgen Kokke explains in
more detail in his statement,
we continued to successfully
implement our strategic
priorities in FY26. The highlights
included regulatory approval
in Canada to use the gene
edit in our EverThrive
®
PRRS-
Resistant Pig (‘PRP’). While
we are getting closer to our
goal of commercialisation in
North America, we still require
approvals in other critical
countries and continued work
on consumer acceptance.
This means the benefits of
PRP will not be reflected in our
results for two to three years.
The formation of our Chinese
joint venture with BCA was a
major development. BCA is an
excellent partner, as a state-
backed and vertically integrated
food business, spanning farming
through to superstores. The joint
venture is committed to using
our genetics and management
support, and we believe that
• Strong financial performance and balance sheet
• Continued successful strategic implementation
• Ongoing succession planning for the Board,
with three new Directors appointed
• Culture and values support our success
QUICK READ
This was another positive
year. Our focus on
consistent execution is
reflected in the results and
our significant strategic
achievements in FY26.
Iain Ferguson CBE
Chairman
Dividend (pence per share)
35.2p
2025: 32.0p +10%
Iain Ferguson CBE
Chairman
9Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Chairman’s Statement continued
ABS has largely concluded the
VAP and is now a fitter business,
with a structure better aligned to
its markets. We will continue to
streamline its operations, while
focusing on revenue growth
through commercial excellence.
ABS has had real success with
IntelliGen, including a major
new contract in India in FY26,
as well as with beef-on-dairy
genetics. These help to insulate
dairy farmers from fluctuating
commodity prices, by giving
them another income stream.
Our R&D function has done
a fantastic job of aligning its
programmes with the needs
of our businesses. The Board
attended an Innovation Day
with the R&D teams in June 2026
and saw a fascinating blend of
longer-term work, for example
in disease resistance, as well as
nearer-term focus areas such
as speeding up the cycle for
genetic improvements in ABS.
The Board
There were three changes to
the Board in FY26. As I noted in
last year’s report, Andy Russell
joined us as CFO in August 2025.
He has settled in well and is
making a strong contribution.
We also recruited two Non-
Executive Directors, Dr Celia
Baxter and Dr Bob Reiter, as
part of our ongoing succession
planning. Celia has deep
experience in human resources,
which we had identified as a
necessary skill for the Board.
Bob’s scientific expertise is
essential for the Board and
highly valuable to our R&D
leadership. Importantly, he is
based in the US, where our
two divisions and R&D are
headquartered. We are in the
process of recruiting a further
Non-Executive Director, who
will take on Lysanne Gray’s role
as Chair of the Audit & Risk
Committee in due course. See
the Corporate Governance
and Nomination Committee
reports for more information.
People and culture
Management has continued to
embed the Group’s values, led
by Jorgen’s consistent focus on
our values and events such as
our ValuesFest and Values World
Cup. The Board regularly sees
the values in place during our
visits to the Group’s sites, and we
gained further evidence of the
strength of our culture through
the biannual employee survey.
More information can be found
in Jorgen’s statement and the
People section of this report.
We invest in all our people
and value their contribution
to the Group’s success. On
the Board’s behalf, I thank
everyone in Genus for their
continued hard work in FY26.
Looking forward
The Board keeps a close
watch on geopolitical issues
and how they might affect
Genus. While uncertainty has
increased in the last 12 months,
the Group has demonstrated
over many years that it can
navigate difficult issues.
The fundamentals of our
markets remain strong and
new trends, such as the
rapid take-up of weight loss
medication, are encouraging
people towards higher-
protein diets. Our continued
successful implementation of
our strategy and our leadership
in elite genetics mean we are
confident of making further
progress in the coming year.
Iain Ferguson CBE
Chairman
We invest in all our
people and value their
contribution to the
Group’s success.
10Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Chief Executive's Review
Group performance
Group revenue was £658.1m
(FY25: £672.8m). The reduction
in revenue was primarily caused
by deconsolidation of PIC China
from 31 January 2026, following
its transfer to our new joint
venture with BCA. Excluding
PIC China, Group revenue was
flat in constant currency and
down 1% in actual currency.
Adjusted PBT increased by
30% in constant currency (+35%
in actual currency), including
a £5.6m milestone payment
from BCA. Statutory PBT was
£282m higher at £310.5m
primarily reflecting the gain
recognised on the formation
of the PIC China joint venture
together with continued
strong operating performance
across ABS and PIC.
PIC performed well in every
region, with volumes up 12%.
Royalty revenue grew 1% with
adjusted royalty revenue,
comprising PIC royalty revenue
and PIC's share of joint venture
royalty revenue, as if the
China joint venture had been
established before 1 July 2024,
rose 5% to £196.9m. Adjusted
operating profit (including
joint ventures and milestone
payments) increased by
16% in constant currency.
PIC grew strongly in Asia, driven
by higher royalty revenues and
increased volumes in China, as
well as good progress in Vietnam
and the Philippines. We see
excellent long-term prospects
in Southeast Asia, where we
currently have low market shares
and an opportunity to grow our
footprints. Latin America also
grew rapidly, particularly in Brazil
where we have a successful
joint venture with Agroceres
and are benefiting from our
excluding the BCA milestone,
equating to 11% of revenue.
Research expenditure was 2% of
revenue as we have refocused
our activities and increased
alignment with the business
units. Product development
investment was 8% of revenue,
underlining our commitment
to growth, improving our value
proposition for customers and
enhancing the sustainability
of animal protein production.
We generated strong free
cash flow of £62.0m, up from
£40.9m in FY25. We also
received net cash proceeds of
£98m following the formation
of our porcine joint venture in
China. As a result, year-end
leverage stood at 0.4 times
compared to our unchanged
target leverage range of one
to two times EBITDA. Our
focus on cash generation
has driven a significantly
strengthened balance sheet
and in accordance with our
capital allocation framework
we will be commencing a £60m
share buyback programme to
be completed during FY27.
Our people and culture
Our people are fundamental to
our performance and strategic
progress, and I want to thank
everyone for their contribution
and dedication. This year’s
employee survey scored strongly
on values and showed we
had made good progress with
strengthening our culture since
the previous survey in FY24.
Other highlights included our
people’s understanding of our
strategy and our commitment
to health and safety.
investment in prior years. Growth
in Brazil was driven by domestic
demand, market share gains
and strong performance in
export markets. North America
performed well but volumes
were affected by customers
having to manage outbreaks
of PRRS. Growth in EMEA was
also positive despite African
Swine Fever cases in Spain’s
wild boar population and other
reported cases across Europe.
ABS Revenue was 2% lower
in constant currency. Milk
prices declined in many
regions resulting in decreased
demand for sexed semen from
dairy customers. Against this
backdrop, ABS volume grew 1%
with sexed volume growing 2%.
Results in Asia were weaker, as
China’s restrictions on bovine
genetic imports from the US
effectively closed this market
during the year. We were
pleased to sign a significant
contract in India for IntelliGen,
enabling millions of small
dairy farmers to produce more
female calves by choice. The
new contract signed with the
state of Uttar Pradesh runs for
five years, thereby improving
the socio-economic status of
countless rural households.
Operating profit including
JVs in ABS increased by 11%
in constant currency, with
VAP initiatives contributing
£9m in the year. Phase 3 was
executed well and generated
£7m of benefit in FY26 and an
annualised benefit of £9m.
We continue to invest
substantially in R&D, with
total investment in the year,
• PIC performed strongly in every region
• ABS benefited from VAP and is now focused on
revenue growth
• Formed Chinese JV with BCA and received further
approvals for PRP gene edit
• Profit growth expected in both businesses in FY27
QUICK READ
This was a year of strong
operational and financial
performance, coupled with
excellent progress on our
strategic priorities.
Jorgen Kokke
Chief Executive
Further reading
on our website
genusplc.com
Key insights overview
Scan the QR code
to watch the video
genusplc.com/investors/annual-report/
Jorgen Kokke
Chief Executive
11Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Chief Executive's Review continued
DELIVERING OUR STRATEGIC PRIORITIES
We made further significant progress with our strategic priorities during the year.
We have continued to reinforce
the values we launched in
FY25, including through our
award-winning ValuesFest
culture campaign. This initiative
aimed to drive employee
engagement and further
strengthen our culture by inviting
employees to celebrate our
values and submit creative
works that reflected their
unique interpretation of them.
We also launched our new
intranet called InGenus, to
make communication with
our employees seamless and
create a better way to work
together. It gives our people a
single place to find information
on business developments, our
polices and employee resources,
and includes AI-powered
search, dynamic translation to
support our global workforce
and mobile access. We are
seeing strong adoption and
receiving excellent feedback.
Sustainability
Driving continuous genetic
improvement is directly
linked to better sustainability
performance for beef, dairy and
pork producers. Our genetics
enable farmers to produce more
high-quality animal protein using
fewer scarce resources, such as
feed, water and land. Scientific
advances including PRP deliver
improved environmental
outcomes and higher
standards of animal welfare.
We continue to demonstrate
the sustainability benefits of
our genetics through life cycle
assessment (‘LCA’). In FY26,
ABS obtained ISO certification
for its LCA of proprietary beef
lines, confirming that that ABS
NuEra Genetics reduce the
overall environmental footprint
of commercial beef on dairy
programmes in the U.S. and
U.K. by 4.5% to 8.8%. PIC also
completed an LCA in relation
to PRP which found that
eliminating PRRS could reduce
green-house gas emissions by
approximately 5% in the U.S..
Responsible adoption of
Artificial Intelligence
We have done significant work
on AI readiness and are well
placed to take advantage of
this technology throughout our
business. Historically, we have
written our own algorithms and
deployed data scientists across
our product development group,
making us optimistic about AI
as a tool to help us become
even more effective. Our IT
environment is also conducive
to leveraging AI. At the same
time, we are mindful of the risks,
especially around cyber security,
legal and compliance issues, so
our objective is to empower our
teams to use AI responsibly.
Outlook
Despite cyclical weakness in key
agricultural markets, we expect
to deliver resilient underlying
profit growth in the year ahead.
Jorgen Kokke
Chief Executive
9 September 2026
Phase 3 of VAP has been executed well and delivered £7m of benefit in the year and annualised benefits
of £9m. We expect to complete a number of smaller additional VAP workstreams through FY27 H1.
ABS is a leaner business, with a strong product portfolio, great customer relationships, an excellent
reputation and a deep pool of talent. To drive the business forward, we have hired experienced leaders
with a remit to deliver commercial and operational excellence. Commercial excellence encompasses
salesforce effectiveness, customer segmentation, pricing and customer profitability. In our operations,
we are implementing LEAN principles and driving efficiencies throughout the supply chain.
Our ambition for ABS remains unchanged as we continue to target double-digit operating margins
in the medium term.
03
Drive greater
value from bovine
Link to strategic framework:
Deliver a differentiated proprietary genetic offering
Focus on progressive protein producers globally
Sustainability at the heart of our business
Share in the value delivered
On 31 January 2026, we formed a joint venture with BCA, transferring PIC China to the new venture
in exchange for a 49% holding and net cash proceeds of £98m. This is a major achievement, which
localises our business, accelerates the long-term growth opportunity in China and cements both
parties’ commitment to achieving PRP commercialisation. The joint venture has a five-member
Board and we have the right to appoint two Board members and the CEO.
Genus was already one of the leading players in Chinese porcine genetics but our market penetration
was low. We expect to achieve further market share gains as our genetics demonstrate their value.
01
Continued growth in
porcine, with more stable
growth in China
Link to strategic framework:
During the year we received approvals and/or favourable determinations for the EverThrive
®
PRP from
Argentina, Canada, Uruguay and Peru. We continue to work towards securing approval in Mexico and
Japan, which are major export markets for US pork producers and China. Commercialisation of PRP is
now beginning in certain Latin American countries.
We are also undertaking significant research into consumer acceptance. The results show that 94%
of consumers are open to purchasing pork from gene-edited pigs, with the responsible reduction of
antibiotic use being the greatest motivator. These findings closely align to independent research from
the U.S. Center for Food Integrity and The Food Industry Association.
In our wider R&D programme, key research areas include sexing, reproductive biology and disease-resistant
animals. Our development expenditure is focused on driving ongoing genetic improvement in our elite herds.
02
Successfully commercialise
our PRP gene edit and
deliver attractive returns
from R&D
Link to strategic framework:
12Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Strategic Framework
Delivering
and sharing
in the value
Deliver a differentiated
proprietary genetic offering
Focus on progressive
protein producers globally
Our strategic framework defines our focus
areas to deliver success. We determine the
framework at Group level and implement
it through our business units.
Elite animals
Technology and capabilities
Data
Success drivers
What does success look like?
Genetic gain
Creating superior breeding animals
for farmers, measured against indices
comprising traits that help to drive
farmers’ productivity and sustainability.
Priorities
Deliver successful commercialisation
of PRP, continue to generate returns
from R&D.
Link to KPIs
$4.08
Porcine Genetic
Improvement Index
$863
Genomic Bull Net Merit
Index (NM$)
Global position
Global supply chain
Customer experience
Success drivers
What does success look like?
Volume growth
Growing volumes, particularly with
progressive livestock farmers.
Priorities
Continued growth in porcine,
with more stable growth in China.
Link to KPIs
1%
Dairy & Beef Volume Growth
12%
Porcine Volume Growth
13Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Strategic Framework continued
Our overarching strategy, success drivers (which feed
into the focus areas of our business model), and
associated KPIs are determined at Group level. The
strategy is then implemented at business unit level.
Our overarching business unit priorities and strategic
progress in FY25 can be found on pages 16 to 27
Sustainability lies at the heart of our business. KPIs
marked with the icon on the right are considered by
the Board to be indicative of our progress in this area.
For more information see pages 28 to 48
Share in the
value delivered
Sustainability at the heart
of our business
Value-based pricing
Product validation
Leverage scale
Success drivers
What does success look like?
Profitability
Generating profit resulting from the
performance of our products in
customers’ systems, and growing margin
as we leverage scale and R&D
investment across species.
Priorities
Deliver successful commercialisation of
PRP, continue to generate returns from
R&D investments.
Link to KPIs
£0.60
Adjusted Operating Profit
per Market Pig Equivalent
£0.87
Adjusted Bovine Operating
Profit per Dose
Sustainability analytics
Informed sustainability investments
Success drivers
What does success look like?
Volume growth
Our strategy is underpinned by our approach
to sustainable business and the strength of our
people. The Board measures the performance
of these key areas using the KPIs opposite.
Priorities
Develop Life Cycle Assessments across our
proteins, to demonstrate the environmental
and welfare benefits of our products.
Link to KPIs
5.25
Primary Intensity Ratio
1
Life Cycle Assessment
Completed
14Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
4.08
4.15
4.39
2026
2025
2024
Competitors 766
ABS 788Competitors 687
ABS 863
ABS 716Competitors 614
2026
2025
2024
1%
5%
-6%
2026
2025
2024
12%
10%
3%
2026
2025
2024
Key Performance Indicators
PIC volume growth (%)
Link to strategic priorities:
Dairy and beef
volume growth (%)
Link to strategic priorities:
Genomic bull net
merit index (NM$)
Link to strategic priorities:
Porcine genetic
improvement index (US$)
Link to strategic priorities:
Tracks the growth in the number of commercial
pigs with PIC genetics globally.
Definition: The change in volume of both
direct and royalty animal sales, using a
standardised MPEs measure of commercial
slaughter animals that contain our genetics.
Performance: Market conditions for pork
producers were generally positive. Against this
backdrop, porcine volumes grew by 12%, to
249.6 million MPEs. Strategically important
royalty volumes grew by 6% with growth in
every trading region excluding North America.
Tracks our global unit sales growth in dairy
and beef.
Definition: The change in dairy, beef and
sorted units of semen and embryos delivered
or produced for customers in the year.
Performance: Excluding China, global markets
performed steadily, with modest growth in
both sexed and conventional volumes. Strong
double-digit growth in LATAM offset lower
volumes in China, where bovine genetic import
restrictions from the US impacted performance,
resulting in overall bovine volume growth of 1%
to 26.2 million units.
Measures the genetic quality of our bulls
released to market, based on economically
relevant traits for farmers.
Definition: The average Net Merit Dollar (NM$)
index score of generally available Holstein
commercial bulls launched to the market
compared with the average of the four largest
competitors. Performance is reported on a
two-year rolling basis, reflecting the typical
commercial sales life of a bull. As the NM$
index is periodically updated to incorporate
changes in economic assumptions, trait
weightings and genetic base adjustments,
historical KPI values are recalculated where
appropriate to maintain consistency and
comparability over time.
Performance: Genus continues to improve the
quality of its commercially available bulls to
maintain a leading genetic position in the
dairy industry.
Measures the genetic improvement we achieve
in our porcine nucleus herds, which ultimately
filters down to our customers’ farms.
Definition: The index measures the marginal
improvement in customers’ US$ profitability,
per commercial pig per year, on a rolling
three-year average.
Performance: Genus continues to deliver
strong rates of genetic improvement through
expanding and maintaining a large nucleus
population for high selection intensity, improving
technical processes for genomic evaluation,
implementing precision data collection from
birth to consumer and continuing to add new
traits and data streams.
Deliver a differentiated
proprietary genetic offering
Focus on progressive
protein producers globally
Sustainability at the
heart of our business
Share in the value delivered
Measuring
our success
15Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
0.60
0.55
0.56
2026
2025
2024
0.87
0.75
0.56
2026
2025
2024
5.25
6.23
2026
2025
2024
6.46
82%
70%
76%
2026
2024
2022
Key Performance Indicators continued
Engagement
survey results
Link to strategic priorities:
Primary intensity ratio
Link to strategic priorities:
Bovine adjusted
operating profit
per dose (£)
Link to strategic priorities:
Adjusted operating
profit per market pig
equivalent (£)
Link to strategic priorities:
Measures levels of employee engagement
over time.
Definition: Employees’ response to the
statement “I would recommend a friend
to work at Genus”.
Performance: Our employee engagement
survey, Your Voice, is conducted every two
years. Our FY25 edition took place amid
extensive transformation across the company,
which inevitably impacted people and
engagement. Despite this, global engagement
remains high and we are strengthening it
further by pursuing opportunities for
improvement identified through the survey.
Measures the emissions intensity of the
Group’s operations, which are largely
driven by animal weight.
Definition: The primary intensity ratio is
a measure of the Group’s Scope 1 and 2
emissions per tonne of animal weight.
Performance: The primary intensity ratio
decreased from 6.23 in FY25 (restated) to
5.25 in FY26, a 15.7% reduction compared
with the prior year.
Monitors bovine profitability per unit.
Definition: Bovine adjusted operating profit
globally, expressed per unit of semen or
embryo delivered or produced for customers. .
Performance: Operating profit per dose
was £0.87, £0.12 higher (£0.07 higher in constant
currency). The primary driver of performance
growth was operational efficiency
improvements from Genus ABS’s Value
Acceleration Programme (“VAP”) initiatives.
Monitors porcine profitability per unit.
Definition: Net porcine adjusted operating
profit globally, expressed per MPE including
our share of Agroceres PIC, our Brazilian joint
venture and PIC China. Results include 100% of
PIC China for the first seven months of FY26,
prior to the formation of the joint venture, and
our share of earnings and MPES for the
remaining five months of FY26.
Performance: Operating profit per MPE was
£0.60, £0.05 higher year-on-year (up £0.04 in
constant currency), reflecting strong
underlying operating growth and operational
leverage benefiting from lower production
costs. Performance was further supported by
the additional BCA milestone receipt of £5.6m;
excluding this operating profit per MPE would
have been £0.58, £0.03 higher than FY25.
Deliver a differentiated
proprietary genetic offering
Focus on progressive
protein producers globally
Sustainability at the
heart of our business
Share in the value delivered
Measuring
our success
16Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
BUSINESS PRIORITIES
Short term
Grow our core business by accelerating genetic
gain and deepening customer relationships,
while preparing to launch the EverThrive
®
PRP,
our PRRS-resistant pig.
Medium term
Increase customer resilience and efficiency by
offering the EverThrive
®
PRP in target markets
around the world.
Long term
Extend industry leadership by continuing
to increase genetic gain, improve product
performance and enhance resilience of supply.
STRATEGIC PROGRESS IN FY26
Create differentiated
proprietary genetic solutions
• Continued to strengthen genetic leadership of
the industry by driving $4.08 of genetic gain
and introducing 8 new selection traits.
• Accelerated preparations for commercialising
the EverThrive
®
PRP by expanding animal
populations, strengthening supply chains
and enhancing market acceptance work.
• Made further progress in evolving and
embedding the use of visual and behavioural
phenotyping, to strengthen animal
selection processes.
Serve progressive protein
producers effectively
• Formed a joint venture with Beijing Capital
Agribusiness (‘BCA’) to strengthen our positioning
in China and provide the best long-term
positioning for value growth.
• Further strengthened existing key accounts in
China, leading to significant increases in
volumes, revenue and profitability.
• Continued to increase market share across Latin
America, driving particularly strong growth in
Brazil and Mexico.
• Maintained productive relationships with large
and integrated producers across North America
• Made further progress in Asia by expanding
business with customers in Vietnam, the
Philippines and South Korea.
Share in the
value delivered
• Signed more agreements for strategically
important royalty revenue, meaning that 76%
of our global business is now conducted
under these contracts.
• Demonstrated the superior performance of PIC
genetics compared to competitors through 29
product validation trials in 6 countries.
Driving global
growth
Operating Review / PIC
We continue to lead
the industry while
intensifying preparations
for introducing the
EverThrive
®
PRP.
Dr Matt Culbertson
Chief Operating Officer / Genus PIC
17Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Operating Review / PIC continued
Transforming
Swine Genetic
Analysis with
Digital
Phenotyping
Find out how PIC is using
digital phenotyping,
computer vision and artificial
intelligence to transform the
way swine genetic potential
is measured.
Market conditions for pork
producers were mixed during the
year. In North America, producers
generated positive profits
although disease outbreaks,
predominantly caused by PRRS,
were particularly challenging
in the second half. Producers in
Latin America enjoyed a strong
year for profitability with pork
prices supported by strong
export volume. In Europe, pork
prices declined in the second
half as the industry grappled
with disease challenges
but supply continued to be
constrained by ongoing political
and regulatory headwinds to
production. Finally in China, the
market environment was very
challenging for producers with
pork prices being significantly
below break-even levels for
the majority of the year.
Amidst this mixed backdrop for
customers, PIC royalty revenue
increased 1% in constant
currency. Adjusted royalty
revenue, comprising PIC royalty
revenue and PIC’s share of joint
venture royalty revenue, as if
the China joint venture had
been established before 1 July
2024, rose 5% to £196.9m. North
American royalty revenue was
relatively muted at +1% due to
customer disease challenges,
however growth was stronger
elsewhere: LATAM (+3%), EMEA
(+7%), Asia ex-China (+10%) and
Joint Ventures (19%). Within
joint ventures, our equity
share of royalty revenue within
Agroceres PIC and PIC China
grew 7% and 52%, respectively.
Total revenue decreased
2%; excluding the impact of
PIC China deconsolidation,
total revenue increased 1%.
Adjusted operating profit
including JVs increased 16% in
constant currency due to strong
royalty revenue growth in the
trading regions, receipt of a
£5.6m milestone payment from
the Group’s Chinese partner
BCA, non-recurring lower input
costs of £2.8m and the sale of a
farm for £1.9m. Excluding the BCA
milestone payments in FY25 and
FY26, adjusted operating profit
including JVs also increased 16%.
Sterling depreciation, particularly
against the Mexican Peso and
Brazilian Real, resulted in a
£1.3m translation tailwind during
the year. As a result, adjusted
operating profit including JVs
increased 17% in actual currency.
Product development is critical
to further strengthening PIC’s
genetic leadership. During
the year, PIC achieved a
further $4.08 of genetic profit
gain. Investment in product
development decreased 18%
in constant currency, primarily
due to the £5.6m milestone
receipt from BCA. Excluding
milestones received in FY25 and
FY26, product development
cost decreased 11%. Within PIC’s
underlying product development
cost was expenditure of £11.6m
in relation to PRP, an increase
of 15% compared to the prior
year as PIC increased its pre-
commercialisation activities.
12 months ended 30 June
Actual currency
Constant
currency
2026
£m
2025
£m
Change
%
Change
%
Revenue 355.8 362.9 (2) (1.6)
Adj. operating profit pre-product development 137.4 134.9 2 2
Porcine product development expense (27.6) (34.6) (20) (18)
Adj. operating profit exc JV 109.8 100.3 9 9
Adj. operating profit inc JV 130.8 111.9 17 16
Adj. operating margin exc JV 30.9% 27. 6 % 3.3pts 3.0pts
Volumes (MPEs)
249m
2025: 223m +12%
Revenue
£355.8m
2025: £362.9m -2%
Adjusted operating profit
£130.8m
2025: £111.9m +17%
Royalty revenue growth
(constant currency)
+1%
Adjusted operating profit growth
(constant currency)
+16%
Scan QR code
to read full
testimonial
18Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Operating Review / ABS
BUSINESS PRIORITIES
Short term
Consolidate the foundation established by the
ABS Value Acceleration Programme (‘VAP’) to
enable scalable growth.
Medium term
Accelerate growth and value creation across
the global business through consistent
commercial excellence.
Long term
Drive continuous improvement and
embed operational excellence to
strengthen relationships with current
and potential customers.
STRATEGIC PROGRESS IN FY26
Create differentiated
proprietary genetic solutions
• Strengthened our genetic line-up by
embedding genetics from De Novo Genetics
into dairy product development.
• Increased income from sexed genetics, including
double-digit growth in Sexcel Male Beef and
a further rise in processing for third parties
through IntelliGen.
• Obtained ISO certification for our life cycle
assessment of proprietary beef lines, confirming
lower environmental impact than average
beef-on-dairy genetics.
Serve progressive protein
producers effectively
• Implemented the third phase of VAP, delivering
approximately £7m of in-year benefit and
approximately £9m of annualised benefit.
• Reviewed and adjusted our commercial model
in key markets (including the UK, US, and Brazil),
helping us enhance our service to customers
and improve efficiency.
• Delivered strong trading across EMEA and Latin
America as a result of growing relationships with
progressive producers.
• Strengthened customer relationships in India,
including signing a new five-year contract with
the state of Uttar Pradesh (‘UP’) for production of
sexed genetics at ten times previous levels.
• Launched “The ABS Way”, a set of new methods
and working practices designed to embed LEAN
principles and enhance value for customers.
Share in the
value delivered
• Expanded our GENEadvance programme, in
which we are sole partners for large producers,
to cover over 1,000 herds around the world,
generating a 9.5% increase in revenue.
• Continued to ensure strong pricing governance
and established a Pricing function to help
us capture appropriate value across our
product lines.
Building sustainable
success
Our ongoing
transformation work
is positioning us well
for future growth.
Jim Low
Chief Operating Officer / Genus ABS
19Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Operating Review / ABS continued
12 months ended 30 June
Actual currency
Constant
currency
2026
£m
2025
£m
Change
%
Change
%
Revenue 299.8 307.7 (3) (2)
Adj. operating profit pre-product development 47. 7 42.1 13 12
Bovine product development expense (25.1) (23.1) 9 12
Adj. operating profit exc JV 22.6 19.1 18 13
Adj. operating profit inc JV 22.9 19.5 17 11
Adj. operating margin exc JV 7. 5% 6.3% 1.3pts 0.9pts
In aggregate, dairy producers
enjoyed a reasonably positive
first half but saw margins
fall in the second half due to
declining global milk prices.
Beef producers, meanwhile,
enjoyed another very strong
year with beef prices at or
close to record highs due to
continued tight supply dynamics.
Amidst this backdrop, ABS
volume grew 1%. Sexed volume
grew 2% modestly, beef volume
increased 9% and conventional
dairy volume decreased -5%.
Due to the near-term profit
differential between dairy and
beef production, dairy farmers in
some markets substituted sexed
genetics for beef-on-dairy
genetics to prioritise near-term
beef production. This change
in customer demand drove
adverse product mix for ABS but
is expected to stabilise once
the relative profitability of dairy
to beef production normalises.
ABS revenue decreased by 2% in
constant currency but adjusted
operating profit including JVs
increased by 11%, a margin
improvement of 0.9pts. Value
Acceleration Programme (‘VAP’)
initiatives were the primary
driver of ABS’s strong adjusted
operating profit growth and
contributed £9m of benefit in
the year comprising £2m of
annualised Phase 2 benefits
and £7m of in-year Phase 3
benefits. Phase 3 initiatives are
now expected to achieve £9m
of total annualised benefit.
Exceptional restructuring costs
recognised in FY26 in relation
to VAP activities were £8.2m.
The three phases of VAP have
significantly strengthened ABS.
The business is leaner, with
a strong product portfolio,
great customer relationships,
an excellent reputation and
a deep pool of talent. We
now we expect to complete a
number of smaller additional
VAP workstreams through FY27
H1 as our focus increasingly
shifts towards implementing
commercial and operational
excellence to accelerate
growth and achieve our target
of double-digit margins in the
medium term. Commercial
excellence encompasses
salesforce effectiveness,
customer segmentation, pricing
and customer profitability. In our
operations, we are implementing
LEAN principles and will
continue to drive efficiencies
throughout the supply chain.
Spend on bovine product
development increased 12% in
constant currency predominantly
due to higher bull depreciation
and the impact of acquiring the
minority interest in De Novo.
Volumes (m straws)
26.2m
2025: 25.9m +1%
Revenue
£299.8m
2025: £307.7m -3%
Adjusted operating profit
£22.9m
2025: £19.5.m +17%
Sexed volume growth
+2%
Adjusted operating profit growth
(constant currency)
+11%
Helping India’s
Dairy Farmers
Build a More
Productive
Future
Learn how ABS and the
Government of Uttar
Pradesh (UP) in India are
working together to expand
access to Sexcel
®
sexed
semen genetics for dairy
farmers in UP.
Scan QR code
to read full
testimonial
20Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Operating Review / R&D
BUSINESS PRIORITIES
Short term
Obtain further regulatory approvals for
the EverThrive
®
PRP in target markets
around the world.
Medium term
Maximise use of our pioneering technologies,
including our stem-cell-based gene-editing
platform, bovine sexing instrumentation and
reproductive technology.
Long term
Develop or license further technologies that
could accelerate genetic gain, combat livestock
disease or support a more sustainable global
food system.
STRATEGIC PROGRESS IN FY26
Gene
editing
• Achieved regulatory approval for the
EverThrive
®
PRP in Canada, an important
step towards commercialising the product
in North America.
• Maintained positive engagement regarding
the EverThrive
®
PRP with regulators in Mexico,
Japan, China and other international
jurisdictions.
• Harnessed our stem-cell-based gene-editing
platform to accelerate progress on projects to
combat additional diseases, including African
Swine Fever.
Innovative
technology
• Made further progress with evolving our sexing
technology, offering prospective advances in
areas such as skew, throughput and automation.
• Continued to enhance the development and
application of insights from genomic data, to
help our businesses drive genetic gain.
Data
strategy
• Introduced centralised instrument monitoring –
which enables remote interaction with sexing
instruments and rapid intervention if needed –
to our sexing lab in Leeds (US), as a precursor
to deploying the software to support other sites
around the world.
• Continued to strengthen our scientific data
platform, enabling us to integrate more diverse
data sources, improve scalability and accelerate
the deployment of robust insights.
Innovation
in action
We continue to pursue
pioneering solutions
that drive genetic
improvement for
customers.
Dr Elena Rice
Chief Scientific Officer and Head of R&D
21Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Operating Review / R&D continued
The Science and Economic
Promise of PRRS-Resistant Pigs
PRRS has affected pig producers for nearly 40 years.
In this video, leading experts discuss the impact of the
disease and how gene editing could help address one of
the swine industry’s most significant challenges.
Scan QR code
to read full
testimonial
Twelve months ended 30 June
Actual currency
Constant
currency
2026
£m
2025
£m
Change
%
Change
%
Gene editing (3.5) (4.3) (19) (16)
Other research and development (11.2) (12.2) (8) (5)
Net expenditure in R&D (14.7) (16.5) (11) (8)
Net expenditure on R&D
decreased 11% in constant
currency in FY26 and
represented 2.2% of Group
revenue. Net expenditure on
R&D is expected to increase
in FY27 but remain below 3%
of Group revenue. R&D’s key
near-term focus is achieving
PRP regulatory approvals
and in the medium term we
remain excited by opportunities
in disease resistance and
reproductive technology.
22Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
I am pleased to address
shareholders for the first time
in the Annual Report as Chief
Financial Officer. Jorgen has
clearly set out Genus’s strategic
priorities, and we continue to
make good progress against
them. I look forward to playing a
meaningful role in sustaining this
momentum while supporting the
delivery of long-term growth.
FY26 performance
In the year ended 30 June
2026, Group revenue fell 2% in
actual currency (a 2% decrease
in constant currency). Adjusted
operating profit including joint
ventures increased by 25% (21%
in constant currency), reflecting
broad-based growth from PIC, a
£5.6m milestone receipt from BCA
and significant adjusted operating
profit improvement at ABS driven
mainly by VAP initiatives. R&D
investment decreased by 11% (8%
in constant currency) as planned,
reflecting continued focus on the
alignment of R&D workstreams
with Genus’s strategic priorities.
Adjusted profit before tax of
£100.2m increased 35% in actual
currency (30% in constant
currency), with interest expense
decreasing from £18.8m to
£15.8m (a 15%
decrease in
constant currency) primarily
from lower average borrowings.
On a statutory basis, profit
before tax was £310.5m (FY25:
£28.5m). The adjusting items
between the statutory and
adjusted profit before tax had
a significant impact this year
predominantly due to a £204.1m
gain recognised on the sale
of our PIC China business and
£12.8m increase (FY25: £13.3m
decrease) in the non-cash
IAS41 fair value of the Group’s
biological assets and net
exceptional expenses of £5.8m
(FY25: £11.4m net expense). The
full reconciliation can be found
further below. Basic earnings
per share on a statutory basis
were 431.6p (FY25: 29.3p) and
adjusted earnings per share
was 110.3p (FY25: 81.8p).
Exchange rate movements were
a tailwind during the year with
a translation benefit on Group
profit of £3.5m compared with
FY25 primarily driven by the
Mexican Peso and Brazilian Real.
Revenue
Revenue decreased 2% in
actual currency (a 2%
decrease
in constant currency) at
£658.1m (FY25: £672.8m). PIC’s
revenue decreased by 2% (a 2%
decrease in constant currency),
with strategically important
royalty revenue increasing by
1%
in constant currency. In ABS,
revenue decreased by 3% (a 2%
decrease in constant currency)
and sexed revenue increased 1%
in constant currency. The primary
driver of sexed performance in
the second half was dairy farmer
volume substitution from sexed
to beef-on-dairy as a result of
low global milk prices relative
to high global beef prices.
• Record adjusted operating profit, up 17%
• Adjusted earnings per share up 35%
• Very strong free cash generation of £62.0m
(FY25: £40.9m)
• Significant reduction in leverage, to 0.4x
(30 June 2025: 1.5x)
• £60m return of capital announced
• Full-year dividend of 35.2 pence per ordinary
share represents growth of 10%
QUICK READ
Group revenue
£658.1m
2025: £672.8m -2%
Adjusted profit before tax
£100.2m
2025: £74.3m +35%
Adjusted earnings per share
110.3p
2025: 81.8p +35%
Chief Financial Officer’s Review
Further reading
on our website
genusplc.com/investors
Our successful
strategy and robust
cash flow have further
strengthened our
balance sheet, allowing
us to return £60m to
shareholders.
Andy Russell
Chief Financial Officer
Andy Russell
Chief Financial Officer
23Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Chief Financial Officer’s Review continued
Adjusted results
1
Statutory results
Actual currency
Constant
currency
change
%
2
Actual currency
Year ended 30 June
2026
£m
2025
£m
Change
%
2026
£m
2025
£m
Change
%
Revenue 658.1 672.8 (2) (2) 658.1 672.8 (2)
Operating profit 94.8 81.1 17 14 8 7. 3 42.4 106
Operating profit inc JVs 116.0 93.1 25 21
Profit before tax 100.2 74.3 35 30 310.5 28.5 989
Net cash flows from operating
activities
109.5 106.2 3 n/m
3
108.8 106.7 2
Free cash flow
1,
62.0 40.9 52 n/m
3
Basic earnings per share (pence)
110.3 81.8 35 30 431.6 29.3 1373
Dividend per share (pence) 35.2 32.0 10
1 Includes share of adjusted pre-tax profits of joint ventures and removes share of adjusted profits of non-controlling interests.
2 Prior year period restated. Please see note 1 of the notes to the condensed set of Financial Statements changes of reportable segments.
3 n/m = not meaningful.
Adjusted operating profit including JVs
1
Actual currency
Constant
currency
change
%
Year ended 30 June
Adjusted profit before tax
1
2026
£m
2025
2
£m
Change
%
Genus PIC 130.8 111.9 17 16
Genus ABS 22.9 19.5 17 11
R&D (14.7) (16.5) 11 8
Central costs (23.0) (21.8) (5) (7)
Adjusted operating profit inc JVs 116.0 93.1 25 21
Net finance costs (15.8) (18.8) 15 15
Adjusted profit before tax 100.2 74.3 35 30
1 Includes share of adjusted pre-tax profits of joint ventures and removes share of adjusted profits of non-controlling interests.
Adjusted operating profit including joint ventures was £116.0m (FY25: £93.1m), a 21% increase in constant
currency. PIC’s adjusted operating profit including joint ventures increased by 16%
in constant currency with
growth in LATAM, Europe and Asia partially offset by modestly lower profit in NAM due to customer and
multiplier health challenges. Underlying PRP spend increased in the year due to increased pre-
commercialisation activity but this was more than offset by the receipt of a £5.6m milestone payment
from the Group’s Chinese partner, BCA. ABS’s adjusted operating profit increased by 11% in constant
currency driven by VAP initiatives that delivered £9.0m of benefit in the year. Investment in R&D decreased
by 8% in constant currency, as planned, reflecting continued focus on the alignment of R&D workstreams
with Genus’s strategic priorities, and central costs increased £1.2m. The Group’s share of adjusted joint
venture operating profit, primarily from our Brazilian joint venture with Agroceres, was significantly higher
than the prior year at £21.2m (FY25: £12.0m).
Net finance costs
Net finance costs decreased to £15.8m (FY25: £18.3m), due to a favourable interest rate variance of £0.9m,
resulting from a reduction in average interest rates to 5.86% (2025: 6.26%) and a favourable average borrowings
variance of £1.3m due to a decrease in average borrowings during the year to £221.1m (FY25: £243.6m). IFRS 16
finance lease interest decreased by £0.6m to £1.8m (2025: £2.4m), primarily due to the reduction in group lease
liabilities, arising from the disposal of a majority interest in PIC China in January 2026.
Amortisation costs in the year were £0.9m (2025: £0.9m) and within other interest there discount interest unwind
on the Group’s pension liabilities and put options totalling £0.4m (2025: £0.4m). Net foreign interest in the year
was an income of £0.3m (2025: income of £0.1m).
Statutory profit before tax
Statutory profit before tax was £310.5m (2025: £28.5m), increased significantly year on year with a gain of
£204.1m from the 51% disposal of PIC China to form a strategic joint venture, higher adjusted profit
performance, increase in biological asset value and lower net exceptional expenses.
The Group’s net IAS 41 valuation of biological assets comprised a £14.5m increase (FY25: £1.7m reduction) in
porcine biological assets, with percentagean increase in retained interest benefitting from large customer
restocking’s after health breaks being partially offset by an increase in risk adjusted discount rate, and a £1.3m
reduction (FY25: £11.6m reduction) in bovine biological assets, reflecting an increase in the risk adjusted
discount rate and lower estimates, based on market data, of the semen sales price attributable to the
biological asset value sales estimates being partially offset by lower production costs. Share-based payment
expense was £10.4m (FY25: £6.9m).
These reconciling items are primarily non-cash, can be volatile and do not correlate to the underlying trading
performance in the year.
The table below reconciles adjusted profit before tax to statutory profit before tax:
2026
£m
2025
£m
Adjusted profit before tax 100.2 74.3
Operating loss attributable to non-controlling interest 0.2 –
Net IAS 41 valuation movement on biological assets in JVs and associates 24.3 (0.9)
Tax on JVs and associates (11.0) (2.0)
Adjusting items:
Net IAS 41 valuation movement on biological assets 12.8 (13.3)
Amortisation of acquired intangible assets (4.1) (5.6)
Impairment of goodwill – (1.5)
Share-based payment expense (10.4) (6.9)
Other gains and losses 204.3 (4.2)
Exceptional items (5.8) (11.4)
Statutory profit before tax 310.5 28.5
24Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Chief Financial Officer’s Review continued
Exceptional items
There was a £5.8m net exceptional expense in FY26 (FY25: £11.4m net expense). As part of ABS’s VAP,
significant one-off expenses of £8.2m were recognised in relation to staff redundancies and consultancy
fees. Outside of VAP, a pension credit of £2.7m was recognised during the year as well £0.3m of
exceptional cost in relation to litigation expenses.
Taxation
The statutory profit tax charge for the year was £36.0m (FY25: £11.2m) including the Group’s share of
income tax of equity accounted investees. This represented an effective tax rate (ETR) of 11.2% (2025:
36.7%). The decrease in the statutory ETR of 25.5 points was principally driven by the non-taxable gain
recognised on the formation of the PIC China joint venture, which qualifies for exemption under the UK’s
Substantial Shareholding Exemption regime. The rate was also favourably impacted by the recognition of
a deferred tax asset in respect of corporate interest restriction amounts following the reduction in Group
debt and the resulting improvement in forecast interest capacity utilisation.
The adjusted profit tax charge for the year of £27.3m (2025: £20.4m) represents an ETR on adjusted
profits of 27.2% (2025: 27.5%). The Group adjusted ETR of 27.2% is higher than the UK statutory rate of 25%,
primarily due to the jurisdictional mix of profits, with a greater share of taxable income arising in territories
with tax rates above the Group average. The expected adjusted profit for the Group in FY27 is in the
range of 26–28%.
Earnings per share
Adjusted basic earnings per share increased by 35% (30% in constant currency) to 110.3 pence (FY25:
81.8 pence). Basic earnings per share on a statutory basis was 431.6 pence (FY25: 29.3 pence), taking
into account the factors noted in the reconciliation between adjusted and statutory profit before tax.
Biological assets
A feature of the Group’s net assets is its substantial investment in biological assets, which under IAS 41 are
stated at fair value. At 30 June 2026, the carrying value of biological assets was £270.6m (2025: £268.3m),
as set out in the table above.
The movement in the overall balance sheet carrying value of biological assets of £2.3m includes the effect
of an exchange rate translation increase of £5.7m. Excluding the translation effect there was a net fair
value impact of:
• a £0.3m decrease in the carrying value of porcine biological assets, with the deconsolidation of the
biological assets held in PIC China business and an increase in the risk adjusted discount rate being
partially offset by an increase in a retained interest benefitting from large customer restocking’s after
health breaks; and
• a £3.1m decrease in the bovine biological assets carrying value, primarily reflecting an increase in the risk
adjusted discount rate and lower estimates, based on market data, of the semen sales price attributable
to the biological asset value sales estimates being partially offset by lower production costs.
The historical cost of these assets, less depreciation, was £81.8m at 30 June 2026 (2025: £82.8m), which is
the basis used for the adjusted results. The historical cost depreciation of these assets included in
adjusted results was £19.0m (FY25: £16.4m).
As at 30 June
2026
£m
2025
£m
Non-current assets 218.7 219.0
Current assets 35.9 34.7
Inventory 16.0 14.6
270.6 268.3
Represented by: 209.3
Porcine 212.8 59.0
Dairy and beef 5 7. 8 268.3
Retirement benefit obligations
The Group’s net retirement benefit obligations at 30 June 2026 were £4.4m (2025: £6.9m) before tax and
£3.3m (2025: £5.7m) net of related deferred tax. The largest element of this liability now relates to some
legacy unfunded pension commitments dating prior to Genus’s acquisition of PIC. Pension liabilities are
stated net of a £2.7m surplus (2025: Nil) in the Dalgety Pension Fund which was recognised during the year,
following a decision by the Trustee of the fund to return any surplus assets to the Principal employer during
the course of winding-up the scheme. Receipt of this surplus from the Trustee, net of any applicable tax
withholding, is expected in the third quarter of 2026.
Robust investment strategies mean our two main defined benefit obligation schemes have remained in
sound financial positions. Prior to any IFRIC 14 amendments, both the Dalgety Pension Fund (“DPF”) and
our share of the Milk Pension Fund reported IAS 19 surpluses. Formal notice to wind-up the DPF was given
by the scheme’s sponsoring employers on 13 February 2025, as all member benefits have now been
secured with insurance companies, following the completion of the GMP equalisation exercise. Wind-up
is expected to complete in the last quarter of 2026.
25Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Chief Financial Officer’s Review continued
Cash flow
Adjusted cash from operating activities of £109.5 (FY25: £106.2m), was driven by strong growth in adjusted
EBITDA, which reached £130.9m (FY25: £119.8m). This was partially offset by a working capital outflow of
£10.8m (FY25: £11.3m inflow) primarily due to phasing of receivables and performance-related pay
accruals, with FY25 also benefitting from implementation of enhanced inventory management within
the ABS business.
Biological assets and net capital expenditures were stable during the year supporting a strong cash
conversion of 94% (FY25: 114%). This metric remains well in excess of our annual target for cash flow
conversion of at least 70%, which we also expect to exceed in this coming year.
Free cash flow, including lease repayments, totalled £62.0 (FY25: £40.9m) and was a new record for
the company.
Year ended 30 June
2026
£m
2025
£m
Adjusted EBITDA 130.9 119.8
Cash received from joint ventures 16.1 6.1
Working capital (10.8) 11.3
Biological assets 1.9 1.3
Net capital expenditure (16.0) (18.2)
Lease repayments (12.6) (14.1)
Adjusted cash from operating activities 109.5 106.2
Cash conversion % 94% 114%
Exceptional items (12.5) (24.2)
Pension contributions, provisions & other (0.6) (1.6)
Interest and tax paid (34.4) (39.5)
Free cash flow inc. lease repayments 62.0 40.9
PIC China 51% disposal net of
withholding tax 9 7. 7 –
Acquisitions, investments & net JV loans – (4.3)
Dividends (21.7) (21.1)
Net cash flow before non-lease
debt repayments 138.0 15.5
Credit facilities and net debt
At 30 June 2026, Genus had headroom of £263.8m in its combined facilities (2025: £119.4m).
The Group’s Facilities Agreement comprises a £220m multi-currency revolving credit facility (‘RCF’) and a
USD 150 million RCF. On 3 June 2026 the Company exercised an option to extend the facility maturation
date by one year to 9 June 2030. A second option, with an exercise date of one month prior to 10 June
2027, exists to extend the maturity date by a further year. The facility also includes an uncommitted £100m
accordion feature for future business development opportunities. In addition, the Company has c. £13m of
bilateral facilities in support of its GBP, EUR, and USD pooling arrangements.
Net debt decreased substantially to £71.8m at 30 June 2026 (2025: £228.2m), supported by strong free
cash flow of £62.0m, net cash proceeds of £97.7m from the 51% sale of PIC China into a strategic porcine
joint venture with BCA, after withholding taxes, deal costs and cash retained within the joint venture. Net
debt also benefited from the disposal of £16.4m of PIC China leases to the joint venture. This was partly
offset by dividend payments of £21.7m.
The ratio of Group net debt to adjusted EBITDA, as calculated under our financing facilities, also
decreased substantially to 0.4 times at 30 June 2026 (2025: 1.5 times) with interest cover at 12 times
(2025: 8 times).
Return on adjusted invested capital
In FY26, Group return on adjusted invested capital (‘ROIC’), as defined in the alternative performance
measures glossary, increased to 18.4% (FY25: 15.0% restated). This was predominantly driven by the
strong profit performance, with adjusted operating profit including joint ventures after tax increasing
to £84.4m (FY25: £67.5m), while adjusted invested capital was stable at £458.13m (FY25: £448.6m
restated). FY25 ROIC has been restated to remove biological asset fair value uplifts in Joint Ventures.
Dividend and additional return of capital
The Board is recommending a final dividend of 24.0 pence per ordinary share representing growth of 11%
on the prior year. When combined with the interim dividend, the total full-year dividend of 35.2 pence per
ordinary share represents growth of 10% (FY25: 32.0 pence per share). The full-year dividend of 35.2 pence
per share corresponds to a 32% payout of adjusted earnings per share which is consistent with the Group’s
targeted payout range of 30% to 40% as described in the Group’s interim results statement published in
February 2026.
It is proposed that the final dividend will be paid on 4 December 2026 to the shareholders on the register
at the close of business on 13 November 2026.
In addition to the Group’s ordinary dividend, and in accordance with the Group’s capital allocation
framework, the Board has announced the return of an additional £60m to shareholders. The Group
intends to return this additional capital via a share buyback programme to be executed through FY27.
26Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
People and Culture
QUICK READ
Our success depends on the
contribution of our talented
and committed colleagues
around the world. We share
information on the gender
diversity of our team in the
Governance section on page 49.
Embedding our values
During the year, we continued
to embed the company-wide
values we refreshed in 2024 by
integrating them into a range
of processes, including talent
attraction, onboarding and
performance management.
These values – Collaborate
as One Team, Create Value
for Customers, Innovate with
Purpose, and Never Stop
Improving – also form part of
our global employee handbook,
which sets out expectations
of all Genus employees. For
more information on how the
Board monitors our Company
culture, please see page 57.
We also launched ValuesFest,
a global contest inviting
colleagues to explain what
the values mean to them
though works in four creative
categories: art, photography,
videography and writing. We
received over 100 entries and
over 1,000 employee votes, with
winning submissions coming from
employees across four regions
and seven countries. We shared
all entries with colleagues across
the Company and have used
winning submissions to showcase
our culture to prospective
recruits through LinkedIn. The
initiative recently received
an award from The Academy
of Interactive & Visual Arts.
Recruiting and
developing colleagues
We continue to seek and
attract talented new colleagues
at different career stages.
For example, this year we
brought in 77 people through
our early-stage career
programmes around the
world, including intern, trainee
and graduate schemes.
We also strengthened our range
of development opportunities
to help colleagues learn, grow
and thrive throughout their
time with Genus. This included
adding further content to
our online learning platform,
Genus University, and providing
targeted development
programmes. Examples include
change management training
for nearly 300 colleagues, plus
the piloting of new behavioural-
based interview techniques,
to strengthen the quality and
consistency of hiring decisions.
Our commitment to employee
development supports effective
succession planning. This
enables us to make internal
promotions wherever possible,
facilitating continuity when
vacancies arise and reducing
reliance on external searches.
Inspiring, developing
and empowering our
people to thrive.
Angelle Rosata
Chief Human Resources Officer
77
people brought in through our
early-stage career programmes
36
senior roles filled internally
across our businesses
• Continued to embed our values into core
HR processes
• Ongoing focus on attracting, retaining and
developing talent
• High levels of employee engagement, with
activities underway to respond to feedback
• Continued to encourage ‘near miss’ reporting,
to help strengthen safety practices
This year we filled 36 senior roles
internally, across our businesses
and central functions.
Further information regarding the
diversity of our workforce is set
out in the Nomination Committee
report on pages 65 to 68.
During the year, we ran
mandatory annual training
for employees on our Code of
Conduct, Animal Well-Being,
Workplace Harassment and
Health & Safety. In addition,
many employees undertake
role-specific training.
Angelle Rosata
Chief Human Resources Officer
27Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
People and Culture continued
Improving communication
We continued to strengthen
internal communication
practices by embracing new
technology. This included
introducing a new global
intranet, named InGenus by our
colleagues, to help them better
connect and collaborate.
Our other channels for employee
dialogue included regular Town
Hall meetings, listening sessions
and Q&As with executive
leaders during site visits. Non-
Executive Directors Lesley Knox
and Lysanne Gray, who are the
Board’s Workforce Engagement
Directors, held discussion
sessions with employees at our
sites in DeForest and Stapeley.
They were joined by fellow NED
Celia Baxter and shared the
feedback with Board members
and executive leaders.
We also continued to support
our employee resource group,
AWAKE (Advancing Women’s
Advocacy, Knowledge and
Empowerment), which held
several in-person and online
discussion and learning events
during the year. This included
a panel event to celebrate
International Women’s Day,
featuring representatives
from the Genus Executive
Leadership Team.
Evaluating engagement
In November 2025, we ran the
latest edition of Your Voice, our
global employee engagement
survey, to seek feedback on
what is working well at Genus
and what could be improved.
Nearly 2,500 colleagues took
part, equivalent to 78% of our
global workforce. They gave
us very positive feedback on
areas such as alignment with
our values, understanding of
strategy and our approach to
health and safety. The survey
also highlighted progress made
on priorities identified in 2023,
including steps to strengthen
our culture and enhance
management effectiveness.
We subsequently held a
series of listening sessions
and cross-functional focus
groups to explore themes
from the survey. Teams then
developed local action plans
to build on the strengths and
address opportunities for
improvement. We consolidated
and prioritised plans at global
business and functional levels,
to identify common themes and
the highest-impact actions.
These include continuing to
improve communication and
knowledge sharing, clarifying
paths for progression and
building skills and capabilities.
These plans are now being
put into practice, while across
the Company we continue
to focus on three enduring
global priorities: culture and
values, continuing to enhance
management effectiveness
and further emphasis on talent
development. The Genus
Executive Leadership Team
is monitoring the impact of
initiatives introduced, whether
these are Company-wide or
within business units or functions.
Health and safety
Our global recordable incident
rate (based on number of
incidents per 100 employees)
closed FY26 at 2.49, above
our target of 1.91. This was
due to some localized issues
and low-severity incidents,
including slips and trips partly
influenced by severe weather
conditions. It also reflected
a 5% increase in proactive
reporting of near-misses and
observations following further
communication and training to
encourage more reporting and
greater employee engagement.
Routes for raising concerns
Colleagues in any part of our
company can raise any concerns
or suspicions about illegal or
unethical behaviour through
several channels. These include
their manager, HR Business
Partner, Legal contact or the
Compliance team. Alternatively,
we offer an independent,
confidential and anonymous
hotline (Speak Up), supporting
our whistleblowing policy, which
is accessible by both telephone
and web portal, and is available
in multiple languages.
Any reports are reviewed by
the Chief Counsel Compliance,
who then notifies the Group
General Counsel and Company
Secretary. Depending on the
nature of the report, the issues
raised may be investigated
and discussed with the Chief
Human Resources Officer, Head
of Risk Management, Internal
Audit and the Company’s
Audit & Risk Committee. This
process is regularly reviewed
as part of our annual Audit &
Risk Committee activity. You
can read more about this
Committee on pages 69 to 73.
Human rights
Genus is committed to
respecting the human rights of
workers throughout our value
chain and the communities in
which we operate and which
are affected by our activities.
We are also committed to
ensuring that anyone who
might be affected by Genus
can enjoy the human rights
described in the International
Bill of Human Rights and the ILO
Declaration on Fundamental
Principles and Rights at Work.
We monitor this through our
established risk management
and internal audit processes,
including periodic risk
assessments. No material issues
were identified during the year.
78%
of our workforce took part in our
employee engagement survey
5%
increase in proactive reporting
of health and safety near-
misses and observations
ValuesFest:
How Employees
Brought Our
Values to Life
See how employees
around the world brought
our Genus Values to life
through creativity,
storytelling and personal
expression. View winning
entries on our website.
Scan QR code
to watch the
full video
28Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Advancing
sustainable
nutrition
IN THIS SECTION
Greenhouse Gas Emissions 
TCFD Report 
GLOSSARY
Animal Weight Intensity Ratio: The sum of scope
1 and scope 2 emissions (measured in tonnes of
CO
2
equivalent) divided by animal weight
(measured in tonnes)
Revenue Intensity Ratio: The sum of scope 1
and scope 2 emissions (measured in tonnes of
CO
2
equivalent) divided by Group revenue
(measured in £m)
Primary Intensity Ratio: The Animal Weight
Intensity Ratio
Scope 1 emissions: Direct greenhouse gas
(‘GHG’) emissions from sources owned
or controlled by Genus, such as livestock
emissions and emissions from fuel used for
fleet and facilities
Scope 2 emissions: Indirect GHG emissions from
the generation of purchased electricity, steam,
heat or cooling that Genus uses in its facilities or
fleet vehicles
Scope 3 emissions: All other indirect GHG
emissions that occur across Genus’s value chain
that are not owned or controlled by Genus, such
as outsourced transportation of animals
Location-based scope 2 emissions: Emissions
from the use of imported electricity calculated
using the average emissions intensity of the local
power grid providing the electricity
Market-based scope 2 emissions: Rather than
using average emission intensities, this method
calculates scope 2 emissions using contracts,
supplier-specific data, and Energy Attribute
Certificates (EACs)
tCO
2
e: Tonnes of carbon dioxide equivalent,
a standard measure of GHG emissions,
representing the global warming impact of
various greenhouse gases
TCFD: Task Force on Climate-related Financial
Disclosures; a framework for corporate disclosure
of climate-related risks and opportunities
Sustainability Report
29Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
Our products and services help farmers
raise more productive and efficient
animals that produce more high-quality
protein per unit of input, such as feed or
water. Our elite pigs, for instance, grow
faster and convert feed to protein more
efficiently than non-elite pigs. Daughters
of our elite bulls produce greater volume
of high-quality milk than non-elite cows.
Driving continuous genetic improvement in our elite herds is therefore
intrinsically linked to improved sustainability outcomes for bovine and
porcine protein producers. This is supported by analysis from the
United Nations Food and Agriculture Organisation
1
which notes that
“The livestock sector requires intensified productivity via improved
genetics and feeding practices…to reduce resource usage.”
Our focus areas
We take a holistic approach to sustainability, focusing on identifying
and reducing GHG emissions in our own operations whilst recognising
the productivity and other gains resulting from use our elite genetics.
Furthermore, we consider our wider environmental impacts and
ensure our operations are underpinned by policies and practices
which reflect our core principles, such as protecting animal well-
being, fostering a dynamic, inclusive and safe working environment,
adhering to ethical business practices and supporting community
causes. Our core policies are supported by mandatory employee
training, delivered and monitored through our online training portal.
GREENHOUSE GAS EMISSIONS
SY26 scope 1 and scope 2 emissions
We have identified GHG emissions as a key environmental impact for Genus. Managing our scope 1 and scope 2 emissions is our primary
focus, as we have more control over them than scope 3 emissions.
Three activity areas produce ~75% of Group scope 1 and 2 (location-based) emissions:
1. Porcine manure management
2. Group imported electricity (facilities)
3. Group fleet
Location-based Market-based
tCO
2
e
% of total scope
1 and 2 tCO
2
e
% of total scope
1 and 2
Total scope 1 and 2 78,829 71,739
PIC manure management 32,780 41.6% 32,780 45.7%
Group electricity (facilities)
2
13,652 17.3% 6,561 9.1%
Group fleet 12,565 15.9% 12,565 17.5%
Total 74.8% 72.4%
In SY26 Genus purchased and retired 10,900 MWh of Energy Attribute Certificates (EACs). This included 8,500 MWh of Green Energy Certificates
(GECs) in China from wind and solar generated electricity, and 2,400 MWh of Renewable Energy Certificates (RECs) in the USA from
hydroelectricity. This contributed a 7,171 tCO
2
e reduction to our market-based scope 2 imported electricity emissions compared to the
location-based equivalent.
Although this does reduce the contribution of imported electricity to overall scope 1 and 2 emissions (market-based), we recognise that this is
a non-persistent intervention and must be repeated annually to retain the emissions benefit. As a result, exploring options to persistently
reduce imported electricity emissions remains a key area of focus.
Genus has two emissions targets:
1. A 25% reduction in our primary intensity ratio against our 2019 baseline, by 2030
2. Becoming a net zero greenhouse gas emissions business for scope 1 and scope 2 by 2050
1 Achieving SDG2 without breached the 1.5°C threshold:
A Global Roadmap (10 December 2023).
1 SY26 relates to Genus’s Sustainability Year 2026: April 2025 to March 2026. This is to ensure the required resources are available for sustainability reporting.
2 Market-based scope 2 emissions include a reduction in emissions through use of EACs and a slight increase in emissions due to the UK supplier-based emission factor applied.
Sustainability Report continued
30Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
tCOe
80,000
100,000
60,000
40,000
20,000
0
SY19
Genus’s scope 1 and 2 emissions
Scope 1 Scope 2
(market based)
Scope 1 - Livestock
Scope 1 - Fleet
Scope 1 - Fuel (Energy & Heat)
89,390
87,321
81,765
81,051
77,366
78,968
83,668
SY20 SY21 SY22 SY23 SY24 SY25
71,739
SY26
tCOe
80,000
100,000
60,000
40,000
20,000
0
SY19
Genus’s scope 1 and 2 emissions
Scope 1
Scope 2
(market based)
Scope 1 - Livestock
Scope 1 - Fleet
Scope 1 - Fuel (Energy & Heat)
89,390
87,321
81,765
81,051
77,366
78,968
83,668
SY20 SY21 SY22 SY23 SY24 SY25
71,739
SY26
tCOe
80,000
100,000
60,000
40,000
20,000
0
SY19
Genus’s scope 1 and 2 emissions
Scope 1 Scope 2
(market based)
Scope 1 - Livestock
Scope 1 - Fleet
Scope 1 - Fuel (Energy & Heat)
89,390
87,321
81,765
81,051
77,366
78,968
83,668
SY20 SY21 SY22 SY23 SY24 SY25
71,739
SY26
tCOe
80,000
100,000
60,000
40,000
20,000
0
SY19
Genus’s scope 1 and 2 emissions
Scope 1
Scope 2
(market based)
Scope 1 - Livestock
Scope 1 - Fleet
Scope 1 - Fuel (Energy & Heat)
89,390
87,321
81,765
81,051
77,366
78,968
83,668
SY20 SY21 SY22 SY23 SY24 SY25
71,739
SY26
100
120
60
80
40
20
0
SY19
—
PIR relative to 2019 baseline — 2030 target
SY20 SY21 SY22 SY23 SY24 SY26SY25
a
b
d
f
c
e
In SY26, we produced 71,739 tCO
2
e of scope 1 and scope 2 (market-
based) emissions. This was a 14% decrease on the 83,688 tCO
2
e of
scope 1 and scope 2 emissions that we generated in SY25. The three
key drivers of the decrease were:
1. Reduced emissions from imported electricity across global facilities
by 1,786 tCO
2
e (-12%) combined with the use of EACs, resulting in a
net total reduction of 8,957 tCO
2
e (-58%) scope 2 (market-based)
2. Reduced emissions from the use of fuel for energy and heat in
facilities by 1,250 tCO
2
e (-13%), primarily attributed to lower
consumption in the USA
3. Reduced Fleet emissions by 1,247 tCO
2
e (-9%) largely due to
reduced mileage in the UK and China
SY26 Primary Intensity Ratio
Genus’s Primary Intensity Ratio (‘PIR’) is the Animal Weight Intensity Ratio (‘AWIR’). In SY26, our AWIR declined to 5.25. This was a 15.8% decrease
compared to our restated AWIR of 6.23 in SY25.
Restatement of SY25 AWIR:
During SY26 we identified and corrected an error in the way some animal weight was being reported. This resulted in an overstatement of
porcine weight in SY25 in three sites in North America, totalling 2,286 tonnes. Due to the significant impact on the AWIR, the SY25 Primary
Intensity Ratio was restated from 5.32 to 6.23. Following identification of this error, Genus has worked with the applicable business unit to
implement further controls to ensure accuracy and consistency in animal weight reporting going forward.
Our medium-term emissions target is a 25% reduction in our AWIR against our 2019 baseline by 2030. The SY26 AWIR outcome of 5.25
represents a 44% reduction compared to our 2019 baseline AWIR of 9.37.
a. PIC Manure - 45.7%
b. Group Fleet -17.5%
c. Group Electricity - 9.1%
d. Fuel - 11.6%
e. ABS Livestock - 8.8%
f. PIC Enteric Fermentation - 7.3%
SY26 scope 1 & 2 market-based emissions
Sustainability Report continued
31Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
From animal weight intensity to revenue intensity
Since 2019, Genus has reported against an Animal Weight Intensity
Ratio (AWIR), calculated as scope 1 and scope 2 greenhouse gas
emissions relative to animal weight. A target was established to
reduce this metric by 25% by 2030 from the 2019 baseline. Since 2022,
Genus has consistently beaten this target and has maintained
performance beyond the required reduction level for four consecutive
reporting years.
As a result, Genus undertook a review of the metric’s ongoing
suitability and considered alternative approaches for measuring
and tracking emissions performance. Through this review, it was
determined that AWIR is not a widely used sustainability metric
and can be difficult for investors and other external stakeholders
to interpret or benchmark. In addition, animal weight is not a
direct measure of business value creation, as Genus generates
value primarily through its research, development, and genetic
improvement activities rather than through animal weight itself.
Instead, Genus has concluded that a revenue intensity ratio,
measured as tonnes of CO
2
e per £m of revenue, provides a better
measure of emissions performance. Revenue intensity offers a clearer
link between business growth and carbon efficiency, enabling
shareholders and other stakeholders, including employees, to assess
whether the company is creating greater economic value whilst
reducing the emissions associated with that value creation. Revenue
intensity is also a more widely used metric amongst public companies
and is, therefore, more familiar to investors and other stakeholders
and facilitates comparison with peers and other companies.
Furthermore, revenue is a consistently available and rigorously
audited measure, providing a robust and reliable basis for
performance tracking and external reporting.
Preparing for future reporting –
aligning reporting periods and target setting
Since 2019, Genus has reported its non-financial sustainability
metrics for the period 1 April to 31 March, while its fiscal year runs from
1 July to 30 June. Effective FY27, Genus will align its sustainability
reporting period with its fiscal year. This change will enhance the
connectivity between sustainability and financial reporting, improve
the comparability and transparency of disclosed information, and
support preparation for emerging UK Sustainability Reporting
Standards (UK SRS) requirements. A single reporting period will
also simplify reporting processes, strengthen assurance activities,
improve the relevance of sustainability metrics that incorporate
financial data, and enable stakeholders to assess sustainability
and financial performance over a consistent timeframe.
In addition, 2026 marked a significant change in Genus’s business
structure following the deconsolidation of PIC China and the
formation of a porcine joint venture. The completion of this
transaction, together with the associated financial and sustainability
reporting changes, provides a more stable and representative
basis from which to establish future sustainability targets. As a
result, Genus believes FY27 is an appropriate point at which to
review and refresh its climate performance targets. During the year,
we will develop a new emissions intensity target to replace the
existing AWIR target. The new target will seek to provide a more
meaningful measure of environmental performance, better align
with the evolving structure of the business, and support effective
communication of progress to shareholders and other stakeholders.
Sustainability Report continued
U P S TRE A M A C T IVIT IES REPORTING COMPANY D OW N S T R E AM A C T IVIT I E S
Capital goods
3,079
Purchased
electricity
6,561
Heating & cooling
5
Electric vehicles
13
Livestock emissions
44,282
Company facilities
8,317
Company vehicles
12,565
Transport and
distribution
No data*
Processing of
sold product
No data*
Use of sold
products
No data*
Downstream
leased assets
No data*
Investments
Not applicable
Franchises
No data*
End-of-life
treatment
No data*
Purchased
goods/services
171,231
Business travel
4,844
Waste
3,582
Fuel & energy-
related activities
7,054
Transport and
distribution
9,718
Upstream
leased assets
647
Employee
commuting
No data*
S C O P E 3
(tCO
2
e)
S C O P E 2
( L O C A TION - B A S E D )
(tCO
2
e)
S C OPE 1
(tCO
2
e)
S C OPE 3
(tCO
2
e)
CO
2
N
2
O
CH
4
32Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
SY25 Scope 3 emissions
Our scope 3 emissions include all indirect GHG emissions that occur in the parts of our value chain that
we do not own or control.
Currently we report partial scope 3 emissions and our ambition is to continuously extend the perimeter of
activities that we can effectively measure, record and manage. To date we have focused on upstream
scope 3 emissions.
• In SY26 the total expenditure used to calculate scope 3 emissions from purchased goods and services
decreased. Emissions increased, however, due to changes in the spend-based factors being applied.
The most significant change was as a result of improvements in our financial data collection, which meant
that spend previously allocated to general ‘animal production’ could be disaggregated into bovine and
porcine specific farming activities. These specific farming activities have higher emission factors
compared to general ‘animal production’.
• Scope 3 emissions from capital goods increased as a result of greater spend allocated to fixed assets
and other capital goods procurement categories.
• Scope 3 fuel and energy related activities emissions are the upstream emissions from electricity and fuel
consumed by Genus. As we have imported less electricity this year, and used less fuel, this reduction
tracks with the related scope 1 and 2 reductions.
• In SY26 there was considerably less 3rd party transportation by air of live animals undertaken within PIC
North America operations, driving a reduction in emissions.
• Spend on waste disposal was higher in SY26 compared to SY25. However, in the EPA NAICS emission factor
update (to v1.3) solid waste categories were revised, resulting in a lower emission factor applied.
• Business air travel (passenger-miles) was reduced in SY26, resulting in less emissions.
• In SY26 we have introduced upstream leased assets in our scope 3 footprint.
Scope Activity SY25 (tCO
2
e) SY26 (tCO
2
e)
SY26 vs SY25
(tCO
2
e)
3.1 Purchased goods and services 148,591 171,231 +15%
3.2 Capital goods 2,168 3,079 +42%
3.3 Fuel and energy related activities 8,231 7,054 -14%
3.4 Upstream transport and distribution 12,298 9,718 -21%
3.5 Waste generated in operations 12,448 3,582 -71%
3.6 Business travel 6,622 4,844 -27%
3.8 Upstream leased assets 648 n/a
Total in current perimeter 190,358 200,157 +5%
Sustainability Report continued
33Strategic ReportGenus plc / Annual Report 2026 Corporate Governance Financial Statements Additional Information
SY26 Streamlined Energy and
Carbon Reporting compliance
In line with the UK Government’s reporting requirements, information
on Genus’s GHG emissions and energy consumption is set out in the
SY26 emissions data table and SY26 energy data table on page 33.
We measure our GHG emissions and energy usage across all global
operations. Energy use includes standard electricity imported from
the grid, and renewable energy generated on-site from solar and
biogas. We also measure the underlying energy use from fuels used in
our facilities and fleet. We calculate our greenhouse gas emissions
each quarter, to give the business timely information to identify
trends, take action and monitor the effectiveness of interventions.
In SY26 Genus reported a significant reduction in methane emissions
produced in porcine sites across Brazil as a result of effective
anaerobic digestion infrastructure. Furthermore, at two Brazil sites
there is an increase in the use of biogas generated from porcine
manure as an energy source. This is demonstrated in the reduction of
grid imported electricity at both sites, despite an overall increase in
production levels.
Further energy efficiency actions in the year include localised efforts
to reduce electricity consumption, resulting in 10% reduction in global
grid imported electricity (kWh) and UK fleet efficiency resulting in
fewer miles.
SY26 emissions data table
All values presented are tCO
2
e, unless otherwise specified
SY26 SY25 SY19 (base-year)
Total UK ROW Total UK ROW Total UK ROW
Scope 65,163 2,642 62,521 68,101 3,460 64,641 81,951 3,178 78,773
– Livestock 44,282 809 43,473 44,723 878 43,845
– Fleet 12,565 1,615 10,950 13,811 2,408 11,403
– Fuel (facilities) 8,317 218 8,099 9,567 174 9,3 93
Scope 2 (market-based) 6,575 183 6,392 15,567 196 15,371 7,439 171 7,268
Scope 2 (location-based) 13,666 103 13,563 15,567 196 15,371 7,439 171 7,268
Total Scope 1 & 2
(market-based)
1
71,739 2,825 68,913 83,668 3,656 80,012 89,390 3,349 86,041
Animal weight (tonnes) 13,670 13,430 9,543
AWIR (tCO
2
e/Animal weight
tonnes) 5.25 6.23 9.37
Group revenue (£m)
4
717.4
Revenue Intensity Ratio
(tCO
2
e/£m) 100.0
Partial scope 3
2
200,157 190,358
1 Total scope 1 and 2 emissions include market-based scope 2. In SY26 market-based scope 2 emissions include reductions from use of Energy Attribute Certificates as well as the use
of supplier-based emission factors for UK. In prior years, market-based emissions utilised grid average electricity factors and therefore are the same as
location-based emissions.
2 Scope 3 category 8 (upstream leased assets) emissions not included in SY26 limited assurance.
3 The sustainability year of April to March varies from the financial year of July to June. This is to ensure the required resources are available for sustainability reporting.
4 The revenue presented here is for the period of April 2025 to March 2026 to align to the sustainability reporting year of total scope 1 and 2 emissions. Revenue includes
Group revenue and revenue from PIC Joint Ventures in China and Brazil.
Sustainability Report continued
Electricity data is collected from metered use. Fuel use is reported
based on financial or other records of fuel purchased. We have used
fuel properties provided by the UK Government’s Department for
Energy Security and Net Zero (‘DESNZ’) to determine the typical
calorific values or densities of fuel, to obtain a common energy
metric (kWh).
Our greenhouse gas emissions are calculated and assured in line with
‘Greenhouse Protocol – A Corporate Accounting and Reporting
Standard’ (revised 2015). We apply an equity-based approach to
greenhouse emissions and energy reporting, incorporating operations
across all business units, subsidiaries and joint ventures, and in all
countries in which we operate. Greenhouse gas emissions and energy
which derive from joint ventures are reported at a proportion
equivalent to Genus’s investment in the venture. Further information
on the methodology can be found at genusplc.com in our Basis of
Reporting document.
FY26 Sustainability Data Independent Assurance
We retained DNV Business Assurance Services UK Limited (‘DNV’) to
provide limited assurance over selected information presented in this
2026 Sustainability Report. The scope of the assurance was designed
to focus on assuring the following sustainability KPIs:
• Total Scope 1 greenhouse gas emissions
• Total Scope 2 (location-based) greenhouse gas emissions
• Total Scope 2 (market-based) greenhouse gas emissions
• Partial Scope 3 (categories 1 to 6) greenhouse gas emissions
• Total energy used
• Proportion of female employees in senior professional, scientific and
management bands
• Recordable injury frequency rate
The data period for greenhouse gas emission and energy metrics
is 1 April 2025 to 31 March 2026. The data period for diversity
and health and safety metrics is 1 July 2025 to 30 June 2026
1
.
The SY26 DNV Assurance Statement can be found at
genusplc.com/sustainability/policies-and-reports/.
1 The sustainability year of April to March varies from the financial year of July to June.